8-K: Vivos Therapeutics Granted Nasdaq Continued Listing Subject to Equity Compliance

Vivos Therapeutics has been granted continued listing on Nasdaq, contingent on demonstrating compliance with the minimum stockholders' equity requirement by August 15, 2024.

Summary

• Vivos Therapeutics received a notice from Nasdaq on May 16, 2024, stating they did not meet the minimum stockholders' equity requirement of $2.5 million as of March 31, 2024.
• The company closed a $7.5 million equity private placement on June 10, 2024, and believed they met the equity requirement as of June 25, 2024.
• On June 27, 2024, Vivos met with a Nasdaq Hearings Panel to discuss their compliance and requested continued listing.
• On July 5, 2024, Nasdaq granted continued listing, contingent on Vivos filing their Form 10-Q for the quarter ending June 30, 2024, by August 15, 2024, demonstrating compliance with the equity requirement.
• Vivos is exploring additional equity financing to maintain compliance and anticipates their strategic marketing alliance will positively impact revenue and equity.
• There is a risk that Vivos may not be able to raise sufficient capital or generate enough revenue to maintain compliance, which could lead to delisting.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company secured continued listing, it is still facing significant financial challenges and the risk of delisting remains. The need for further capital raises is a concern.

Positives

• Vivos secured continued listing on Nasdaq, avoiding immediate delisting.
• The company successfully raised $7.5 million through a private placement.
• A strategic marketing alliance is expected to improve revenue and equity.

Negatives

• Vivos initially failed to meet Nasdaq's minimum stockholders' equity requirement.
• There is a risk that the company may not be able to raise sufficient capital or generate enough revenue to maintain compliance.
• Delisting from Nasdaq would have a material adverse effect on the company's stock price, ability to raise capital, and reputation.

Risks

• The company may not be able to raise sufficient capital to maintain compliance with Nasdaq's equity requirement.
• The company may not generate sufficient revenue or operating results to maintain compliance.
• Delisting from Nasdaq would negatively impact the company's stock price, ability to raise capital, and reputation.
• There is no guarantee that the company will be able to maintain compliance with the equity requirement.

Future Outlook

Vivos is working to maintain compliance with Nasdaq's equity requirement, including exploring additional equity financing and leveraging a strategic marketing alliance to improve revenue and equity. However, there is a risk they may not be able to achieve this.

Management Comments

• The company is working diligently to ensure its continued compliance with the Equity Requirement.
• The company anticipates that its previously disclosed strategic marketing and distribution alliance will also positively impact the company's revenue growth and stockholders equity in upcoming fiscal quarters.

Industry Context

This announcement highlights the challenges faced by smaller companies in maintaining listing requirements on major exchanges like Nasdaq, particularly in the current economic climate. It also underscores the importance of strategic partnerships and capital raising for growth and compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, often relying on private placements and strategic partnerships to meet financial requirements.
• Companies like Aytu BioPharma and Diffusion Pharmaceuticals have also faced similar delisting risks due to low stock prices and equity issues, highlighting the commonality of these challenges in the sector.
• The $7.5 million private placement is a typical approach for companies in this situation, but the need for further capital raises indicates ongoing financial pressure.

Stakeholder Impact

• Shareholders face the risk of delisting, which would negatively impact the stock price and their ability to trade shares.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers and suppliers may be impacted by the company's ability to operate effectively if delisted.
• Creditors may be concerned about the company's ability to repay debts if delisted.

Next Steps

• Vivos must file their Form 10-Q for the quarter ended June 30, 2024, by August 15, 2024, demonstrating compliance with the equity requirement.
• The company will continue to explore additional equity financing options.
• The company will work to leverage its strategic marketing alliance to improve revenue and equity.

Key Dates

Keywords

Nasdaq, stockholders equity, compliance, delisting, equity financing, private placement, Form 10-Q, revenue growth, strategic alliance